Citations

Clear

3030 citation(s) found for "Susan, M".

Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.
Pesaran, Tina , Chen, Wenan , Lyra, Paulo C. , Morais Lyra, Paulo Cilas , Couch, Fergus J. , Huang, Huaizhi , Karam, Rachid , Yadav, Siddhartha , Domchek, Susan M. , Monteiro, Álvaro N.A. , Boddicker, Nicholas , Richardson, Marcy E , Hu, Chunling

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 10511-10511

10.1200/jco.2024.42.16_suppl.10511 Get It

10511 Background: Germline BRCA2 loss-of function (LOF) variants identified by clinical genetic testing predispose to breast, ovarian, prostate and pancreatic cancer. However, variants of uncertain significance (VUS) (n > 4000) limit the clinical use of testing results. Thus, there is an urgent need for functional characterization and clinical classification of all BRCA2 variants. Here we report on comprehensive saturation genome editing (SGE)-based functional characterization of 97% of all possible single nucleotide variants (SNVs) in the BRCA2 DNA Binding Domain hotspot encoded by exons 15 to 26 for pathogenic missense variants. Methods: SGE of exons 15 to 26 of BRCA2(MANE transcript ENST00000380152.8) was performed in the haploid human HAP1 cell line. Each exon along with 10bp flanking intronic sequence was studied as an independent target region. The most efficient sgRNA for each target region was selected and cloned into a Cas9 expressing plasmid. Site-saturation mutagenesis (SSM) libraries for each of the 14 target regions were designed to target every nucleotide and were generated by site directed mutagenesis using NNN-tailed PCR primers. HAP1 cells were transfected and harvested at Day5 and 14. Cell survival in response to each variant was assessed based on deep sequence analysis of the surviving endogenously targeted HAP1 cells at Day 5 and Day 14. Results: A total of 7013 SNVs were characterized as functionally abnormal (n = 955), intermediate/uncertain, or functionally normal (n = 5224) based on 95% precision for ClinVar known pathogenic and benign standards. Results were validated relative to batches of nonsense and synonymous variants and variants evaluated using a homology directed repair (HDR) functional assay. Breast cancer case-control association studies showed that pooled SNVs encoding functionally abnormal missense variants were associated with increased risk of breast cancer (odds ratio (OR) 3.89, 95%CI: 2.77-5.51). The functional data were added to other sources of information in a ClinGen/ACMG/AMP-like model and 700 functionally abnormal SNVs, including 220 missense SNVs, were classified as pathogenic or likely pathogenic, while 4862 functionally normal SNVs, including 3084 missense SNVs, were classified as benign or likely benign. Conclusions: The production of functional maps for 97% of all SNVs in the BRCA2 DBD allowed for separation of nucleotide/protein-level functional aberrations. When coupled with genetic and clinical sources of evidence this study led to clinical classification of 5500 individual variants. These data will prove useful in the future, through integration with other datasets, for characterization and clinical classification of all variants in this region in individuals from all racial and ethnic backgrounds and for all BRCA2 associated forms of cancer.
Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use
Fleseriu, Maria , Nachtigall, Lisa B. , Samson, Susan L. , Мелмед, Шломо , Fleseriu, Maria

Mayo Clinic

Expert Review of Endocrinology & Metabolism | June 3, 2024 | Volume: 19 | Issue: 4 | Pages: 367-375

10.1080/17446651.2024.2363540 | PMID 38842362 Get It

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population
Muchtar, Eli , Geyer, Susan, Merlini, Giampaolo , Gertz, Morie A. , Gertz, Morie A , Muchtar, E , Merlini, Giampaolo

Mayo Clinic

Blood | May 31, 2024 | Volume: 144 | Issue: 7 | Pages: 790-793

10.1182/blood.2024024623 | PMID 38820591 Get It

Abstract The survival of patients achieving a cardiac complete response in light chain amyloidosis, defined as N-terminal pro B-type natriuretic peptide ≤350 pg/mL or B-type natriuretic peptide ≤80 pg/mL, was similar to that of a matched general population, with estimated 5-year survival rates of 93% and 95%, respectively.
A Roundtable Discussion on Brain Connectivity
Laureys, Steven , Raichle, Marc, Friston, Karl , Whitfield‐Gabrieli, Susan , Whitwell, Jennifer L. , Calhoun, Vince D. , Douw, Linda , Boly, Mélanie

Mayo Clinic

Brain Connectivity | May 30, 2024 | Volume: 14 | Issue: 5 | Pages: 263-273

10.1089/brain.2024.0037 | PMID 38814819 Get It

ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Leone, José Pablo , Ruddy, Kathryn J. , Rashid, Naim U. , Ortiz-Perez, Tamara, Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Krop, Ian E. , Thompson, Alastair M. , Sukumar, Jasmine S , Giordano, Sharon H. , Gupta, Gaorav P , Hilsenbeck, Susan Galloway , Walsh, Elaine M. , Makhlin, Igor , Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Spanheimer, Philip M. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS632-TPS632

10.1200/jco.2024.42.16_suppl.tps632 Get It

TPS632 Background: Male breast cancer is a rare disease, and most cases are hormone receptor-positive (HR+). Due to a lack of clinical trials, male breast cancer has historically been treated based on data extrapolated from women. However, there are substantial knowledge gaps in the comparative efficacy, safety, and patient-reported outcomes of endocrine therapies for male breast cancer. While tamoxifen is the current standard of care, additional data are warranted for aromatase inhibitors (AI), gonadal suppression, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Methods: This is an open-label, multicenter, randomized, phase II trial designed to evaluate different endocrine therapies in men with HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A total of 60 men will be enrolled across nine (9) sites within the Translational Breast Cancer Research Consortium (TBCRC). Key eligibility criteria include male sex and stage I, II, or III HR+/HER2- breast cancer before surgical resection of the primary tumor and axillary nodes. Key exclusion criteria include prior anti-cancer therapy for the current breast cancer or any other malignancy within the past 12 months, and inflammatory breast cancer. The trial has two phases. The first phase is a window of opportunity component in which newly diagnosed men are randomized 1:1:1 to either tamoxifen (Arm A), anastrozole (Arm B), or anastrozole plus degarelix (Arm C) given for three weeks. The primary endpoint for the window phase is Ki-67 reduction from the baseline diagnostic biopsy to the research biopsy at the end of the window phase. The second phase consists of neoadjuvant treatment, in which the tamoxifen group is randomized 1:1 to tamoxifen (Arm D) versus tamoxifen plus abemaciclib (Arm E), and the anastrozole alone (Arm B) and anastrozole plus degarelix (Arm C) groups are merged and then randomized 1:1 to anastrozole plus degarelix (Arm F) versus anastrozole plus degarelix plus abemaciclib (Arm G). The duration of the neoadjuvant phase is four (4) months, and the primary endpoint of this phase is residual cancer burden (RCB) index at time of surgery. The trial is powered for the RCB endpoint in a 2 x 2 factorial design to detect a 0.6 unit decrease in RCB index with 80% power and alpha=10%. For the Ki-67 endpoint, we assume an approximately 50% reduction in Arms A and B; Arm C will be of interest if it leads to ≥80% reduction in Ki-67. Secondary endpoints include: estradiol and testosterone levels at baseline, end of window, and during neoadjuvant phase; preoperative endocrine prognostic index (PEPI) score at surgery; adverse events; and patient-reported outcomes (including quality of life). Tumor tissue will be collected for correlative analyses. The study opened to enrollment at Dana-Farber in October 2023, and additional sites will open in 2024. Clinical trial information: NCT05501704 .
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Chen, Anran , Kim, Beom-Jun , Mitra, Aparna , Vollert, Craig T. , Fandino, Diana , Anurag, Meenakshi , Holt, Matthew V. , Gou, Xuxu , Pilcher, Jacob B. , Northfelt, Donald W. , Marshall, C. Gary , Hyer, Marc L. , Papp, Robert , Yin, Shou-Yun , Angelis, Carmine De , Cynthia, X. , Lei, Jonathan T , Fandino, Diana , Anurag, Meenakshi , Holt, Matthew V , Gou, Xuxu , Pilcher, Jacob B , Goetz, Matthew P , Northfelt, Donald , Hilsenbeck, Susan Galloway , Marshall, C Gary , Hyer, Marc L , Papp, Robert , Yin, Shou-Yun , De Angelis, Carmine , Schiff, Rachel , Fuqua, Suzanne A W , Ma, Cynthia , Foulds, Charles E , Ellis, Matthew J , Lei, Jonathan T. , Goetz, Matthew P. , Schiff, Rachel , Ellis, Matthew J.

Mayo Clinic

Molecular Cancer Therapeutics | May 23, 2024 | Volume: 23 | Issue: 10 | Pages: 1494-1510

10.1158/1535-7163.mct-23-0564 | PMID 38781103 Get It

Abstract Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however drug resistance is common. In this study, proteogenomic analyses of patient-derived xenografts (PDXs) from patients with 22 ER+ breast cancer demonstrated that protein kinase, membrane-associated tyrosine/threonine one (PKMYT1), a WEE1 homolog, is estradiol (E2) regulated in E2-dependent PDXs and constitutively expressed when growth is E2-independent. In clinical samples, high PKMYT1 mRNA levels associated with resistance to both ET and CDK4/6 inhibition. The PKMYT1 inhibitor lunresertib (RP-6306) with gemcitabine selectively and synergistically reduced the viability of ET and palbociclib-resistant ER+ breast cancer cells without functional p53. In vitro the combination increased DNA damage and apoptosis. In palbociclib-resistant, TP53 mutant PDX-derived organoids and PDXs, RP-6306 with low-dose gemcitabine induced greater tumor volume reduction compared to treatment with either single agent. Our study demonstrates the clinical potential of RP-6306 in combination with gemcitabine for ET and CDK4/6 inhibitor resistant TP53 mutant ER+ breast cancer.
Health equity engineering: Optimizing hope for a new generation of healthcare
Enders, Felicity , Brooks, Tayla R., Carr, Allison R. , Cullen, John P. , DiazGranados, Deborah , Gaba, Ayorkor , Johnson, Leigh , Messinger, Shari , Milam, Adam J. , Perkins, Susan M. , Pineda, Tiffany Danielle , Periyakoil, Vyjeyanthi S. , Hanlon, Alexandra L. , Enders, Felicity T , Golembiewski, Elizabeth H , Cullen, John P , DiazGranados, Deborah , Gaba, Ayorkor , Orellana, Minerva A , Pineda, Tiffany D Chisholm , Milam, Adam J , Messinger, Shari , Golembiewski, Elizabeth H. , Balls‐Berry, Joyce E. , Brooks, Tayla Rashanaye , Menser, Terri , Orellana, Minerva , Thurston, Sally W.

Mayo Clinic

Journal of Clinical and Translational Science | May 22, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.549 | PMID 39478773 Get It

Abstract Medical researchers are increasingly prioritizing the inclusion of underserved communities in clinical studies. However, mere inclusion is not enough. People from underserved communities frequently experience chronic stress that may lead to accelerated biological aging and early morbidity and mortality. It is our hope and intent that the medical community come together to engineer improved health outcomes for vulnerable populations. Here, we introduce Health Equity Engineering (HEE), a comprehensive scientific framework to guide research on the development of tools to identify individuals at risk of poor health outcomes due to chronic stress, the integration of these tools within existing healthcare system infrastructures, and a robust assessment of their effectiveness and sustainability. HEE is anchored in the premise that strategic intervention at the individual level, tailored to the needs of the most at-risk people, can pave the way for achieving equitable health standards at a broader population level. HEE provides a scientific framework guiding health equity research to equip the medical community with a robust set of tools to enhance health equity for current and future generations.
Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023
Hynds, Robert E. , Magin, Chelsea M. , Ikonomou, Laertis , Aschner, Yael , Beers, Michael F. , Burgess, Janette K. , Heise, Rebecca L. , Hume, Patrick S. , Krasnodembskaya, Anna , Mei, Shirley H. J. , Park, Jin‐Ah , Reynolds, Susan D. , Tschumperlin, Daniel J. , Tanneberger, Alicia E. , Waters, Christopher M. , Zettler, Patricia J. , Weiss, Daniel J. , Ryan, Amy L. , Krasnodembskaya, Anna D , Park, Jin-Ah , Tschumperlin, Daniel J , Waters, Christopher M , Ryan, Amy L , Burgess, Janette K , Misharin, Alexander V. , Vaidyanathan, Sriram

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 21, 2024 | Volume: 327 | Issue: 3 | Pages: L327-L340

10.1152/ajplung.00052.2024 | PMID 38772903 Get It

Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of “omics” technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.
Sexual Orientation and Gender Identity Data Collection in Cancer Care: A Nationwide Landscape Assessment Update
Cathcart-Rake, Elizabeth , Jatoi, Aminah , Dressler, Emily V. , Nightingale, Chandylen L. , Neuman, Heather B. , Loh, Kah Poh , Kamen, Charles , Ramsey, Scott D. , McDonald, Andrew M. , Foust, Melyssa , Braun‐Inglis, Christa , Kyono, Wade , Drescher, Charles W. , Wood, Eden G., Ramsey, Scott D. , Cathcart-Rake, Elizabeth J , Weaver, Kathryn E , Nightingale, Chandylen L , Neuman, Heather B , Loh, Kah Poh , Kamen, Charles , Ramsey, Scott , Dressler, Emily V , Kittel, Carol , Weaver, Kathryn E. , Parsons, Susan K. , Obeng‐Gyasi, Samilia , Cooley, Mary E. , Ramsey, Scott D.

Mayo Clinic

JCO Oncology Practice | May 20, 2024 | Volume: 20 | Issue: 9 | Pages: 1272-1279

10.1200/op.23.00724 | PMID 38768413 Get It

PURPOSE Routine collection of sexual orientation (SO) and gender identity (GI; collectively SOGI) in cancer clinics advances cancer care equity. METHODS In 2022, NCI Community Oncology Research Program (NCORP) practice groups were asked about routine collection of SOGI data in the electronic health record. The proportions of practice groups reporting collection of SO and/or GI data were calculated, and practice group characteristics were assessed for associations. RESULTS Of 271 practice groups nationwide, 42% (n = 112) collect SO data, 58% (n = 157) collect GI data, and 35% (n = 96) collect both. In multivariate analyses, SO data collection was associated with practice groups having minority outreach staff (odds ratio [OR], 2.07 [95% CI, 1.12 to 3.81]; P = .02); GI data collection was associated with practice groups located in the Northeastern United States (OR, 2.08 [95% CI, 0.73 to 5.91]; P = .045), and those with a higher proportion of new patients who were White (OR, 1.02 [95% CI, 1.01 to 1.04]; P < .001). Practice groups in the South were least likely to collect SOGI data (OR, 0.49 [95% CI, 0.26 to 0.94]; P = .004). There were no statistically significant differences in SO and/or GI collection on the basis of the practice group's proportion of Medicaid/Medicare patients, number of new patients with cancer per year, or practice ownership. CONCLUSION Slightly over one third of NCORP practice groups report routinely collecting SOGI data. There are regional differences in data collection, underscoring the need to craft targeted, region-specific interventions focused on boosting the capture and recording of SOGI data in an affirming manner.
Precision medicine within health professions education: Defining a research agenda for emergency medicine using a foresight and strategy technique (FaST) review
Chan, Teresa M. , Thoma, Brent , Finnell, John T. , Gordon, Bradley D. , Farrell, Susan , Pusic, Martin , Cabrera, Daniel , Gisondi, Michael A. , Caretta‐Weyer, Holly , Stave, Christopher D , Caretta-Weyer, Holly A , Stave, Christopher , Ankel, Felix , Pusic, Martin V , Cabrera, Daniel , Finnell, John T. , Ankel, Felix

Mayo Clinic

AEM Education and Training | May 20, 2024 | Volume: 8 | Issue: S1 | Pages: No page available

10.1002/aet2.10983 | PMID 38774830 Get It

Abstract Background Precision medicine, sometimes referred to as personalized medicine, is rapidly changing the possibilities for how people will engage health care in the near future. As technology to support precision medicine exponentially develops, there is an urgent need to proactively improve our understanding of precision medicine and pose important research questions (RQs) related to its inclusion in the education and training of future emergency physicians. Methods A seven‐step process was employed to develop a research agenda exploring the intersection of precision and emergency medicine education/training. A literature search of articles about precision medicine was conducted first, which informed the creation of future four scenarios in which trainees and practicing physicians regularly discuss and incorporate precision medicine tools into their discussions and work. Based on these futurist narratives, potential education RQs were generated by an expert panel. A total of 59 initial questions were subsequently categorized and refined to a priority list through a nominal group voting method. The top/priority questions were presented at the 2023 SAEM Consensus Conference on Precision Medicine, Austin, Texas, for further input. Results Eight high‐value education RQs were developed, reflecting a holistic view of the challenges and opportunities for precision medicine education in the knowledge, skills, and attitudes relevant to emergency medicine. These questions contend with topics such as most effective pedagogical methods; intended resulting outcomes and behaviors; the generational differences between practicing emergency physicians, educators, and future trainees; and the desires and expectations of patients. Conclusions Emergency medicine and emergency physicians must be prepared to understand precision medicine and incorporate this information into their “toolbox” of thinking, problem solving, and communication with patients and colleagues. This research agenda on how best to educate future emergency physicians in the use of personalized data to provide optimal health care is the focus of this article.